ClinicalTrials.gg
CompletedNCT01165229Updated Apr 27, 2020Results posted

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A and Placebo in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 213 sites in 18 countries. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-27.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14,819
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
4th of 46
14,819 · median 239
Started
2010
with 3 others
Phase 3
22 of 46
2 open now
Registered
4th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 4th largest by enrollment, is one of 4 that started in 2010, is one of 22 in phase 3, and was the 4th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 70 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years.

Two studies (Zoster-006 [NCT01165177] and Zoster-022 [NCT01165229]) will be conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. This protocol posting also deals with the outcome measures related to the pooled analysis.

Read the detailed description

This protocol summary has been updated following Protocol Amendment 4 changes to study objectives and endpoints. Pooled analyses of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) will only be conducted if the primary objective herpes zoster vaccine efficacy (HZ VE) is demonstrated in both ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) separately.

03

Conditions studied

  • Herpes Zoster
  • Herpes Zoster Vaccine

Browse trials for

Keywords

  • Immunogenicity
  • Subjects 70 years and older
  • Efficacy
  • Herpes Zoster
  • Safety
  • Adults
  • Vaccine
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes will comply with the requirements of the protocol.
  • Written obtained from the subject.
  • A male or female aged 70 years or older at the time of the first vaccination.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy History of HZ.
  • Previous vaccination against varicella or HZ.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period.
  • Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • Acute disease and/or fever at the time of enrolment.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
14,819 participants (actual)

Study arms

  • Experimental
    Zoster vaccine group

    Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule

    Biological: Herpes Zoster Vaccine GSK1437173A

  • Placebo comparator
    Placebo group

    Subjects will receive NaCl solution placebo according to a 0, 2-month schedule

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Any Episodes of Herpes Zoster (HZ)

    Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  2. Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)

    Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  3. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ

    Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

Secondary outcomes

  1. Number of Subjects With Post-herpetic Neuralgia (PHN)

    PHN cases in the mTVc.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  2. Number of Days With Severe 'Worst' HZ-associated Pain

    Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  3. Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations

    The number of subjects with confirmed HZ related mortality and hospitalizations were tabulated.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  4. Number of Subjects With Overall Mortality and HZ-related Mortality

    The number of subjects with overall mortality and HZ related mortality were tabulated. Evaluation of VE in the reduction of overall and HZ related mortality as per study objective was not performed due to low number of events reported.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  5. Number of Subjects With Confirmed HZ Episode Related Hospitalizations

    Incidence of overall and HZ-related hospitalizations during the study.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  6. Number of Subjects With HZ Related Complications

    Incidence of HZ complications during the study in subjects with confirmed HZ.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  7. Number of Subjects Receiving Pain Medication Associated With HZ

    Incidence of use of pain medications throughout the study

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  8. Number of Days With Pain Medication Associated With HZ

    Incidence of reduction of duration of pain medication associated with HZ throughout the study.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  9. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented everyday normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  10. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  11. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within the 30 days (Days 0-29) after each vaccination

  12. Number of Subjects With Any and Related Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Month 0 to Month 14

  13. Number of Subjects With Fatal Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  14. Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication

    The number of subjects with SAEs related to study participation or concomitant GSK medication were tabulated

    Time frame: During the entire study period (3 to 5 year period following day 0)

  15. Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

    Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  16. Number of Subjects With Any and Related Medically Attended Visits

    Occurrence and relationship to vaccination of medically attended visits other than routine health care visits, from Month 0 to Month 8 in all subjects. Medically attended visits were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended visits= Occurrence of any medically attended visits regardless of intensity grade or relation to vaccination.

    Time frame: From Month 0 to Month 8 post-vaccination

  17. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA

    Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  18. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ

    Occurrence of PHN during the entire study period in all subjects with confirmed HZ.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  19. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.

    The duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  20. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.

    Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  21. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  22. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = Temperature\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  23. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any,Grade 3 and Related Unsolicited AEs in Subjects ≥ 70 YOA

    Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within 30 days (Days 0 - 29) after each vaccination

  24. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related SAEs

    Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA. Related SAEs also included any SAEs related to study participation or concurrent GSK medication/vaccine.

    Time frame: From Month 0 to Month 14

  25. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs

    Fatal SAEs during the entire study period in subjects ≥ 70 YOA.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  26. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related pIMDs

    Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.

    Time frame: During the entire study period (3 to 5 year period following Day 0)

  27. Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related Medically Attended Visits

    Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.

    Time frame: From Month 0 to Month 8 post-vaccination

07

Results

Posted Nov 20, 2017

Participant flow

Participant flow — Overall Study
MilestoneZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Started69506950
Completed57705760
Not completed11801190
Withdrew: Serious adverse event456487
Withdrew: Non-serious adverse event4715
Withdrew: Protocol violation68
Withdrew: Withdrawal by subject387396
Withdrew: Migrated/moved from study area5146
Withdrew: Lost to follow-up123133
Withdrew: Suspected hz episode22
Withdrew: No reason from the subject108102
Withdrew: Unknown completion status01

Outcome measures

PrimaryNumber of Subjects With Any Episodes of Herpes Zoster (HZ)

Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Any Episodes of Herpes Zoster (HZ)
ParticipantsZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
Number of Subjects With Any Episodes of Herpes Zoster (HZ)1762316954223
Statistical analysis
  • Zoster-022 GSK1437173A 70-79YOA Group vs Zoster-022 Placebo 70-79YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 90.02 · 95% CI 83.54 to 94.32
  • Zoster-022 GSK1437173A >=80YOA Group vs Zoster-022 Placebo >=80YOA Group · Poisson exact method · p = <0.0001 · Vaccine efficacy: 89.08 · 95% CI 74.65 to 96.16
  • Zoster-022 GSK1437173A >=70YOA Group vs Zoster-022 Placebo >=70YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 89.79 · 95% CI 84.29 to 93.66
PrimaryOutcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)

Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)
ParticipantsZoster-022/006 Pooled GSK1437173A 70-79YOA GroupZoster-022/006 Pooled GSK1437173A >=80YOA GroupZoster-022/006 Pooled GSK1437173A >=70YOA GroupZoster-022/006 Pooled Placebo 70-79YOA GroupZoster-022/006 Pooled Placebo >=80YOA GroupZoster-022/006 Pooled Placebo >=70YOA Group
Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)22429736
Statistical analysis
  • Zoster-022/006 Pooled GSK1437173A 70-79YOA Group vs Zoster-022/006 Pooled Placebo 70-79YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 93.04 · 95% CI 72.47 to 99.19
  • Zoster-022/006 Pooled GSK1437173A >=80YOA Group vs Zoster-022/006 Pooled Placebo >=80YOA Group · Poisson exact test · p = 0.1844 · Vaccine efficacy: 71.16 · 95% CI -51.51 to 97.08
  • Zoster-022/006 Pooled GSK1437173A >=70YOA Group vs Zoster-022/006 Pooled Placebo >=70YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 88.78 · 95% CI 68.70 to 97.10
PrimaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ

Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ
ParticipantsZoster-022/006 Pooled GSK1437173A 70-79YOA GroupZoster-022/006 Pooled GSK1437173A >=80YOA GroupZoster-022/006 Pooled GSK1437173A >=70YOA GroupZoster-022/006 Pooled Placebo 70-79YOA GroupZoster-022/006 Pooled Placebo >=80YOA GroupZoster-022/006 Pooled Placebo >=70YOA Group
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ1962521668284
Statistical analysis
  • Zoster-022/006 Pooled GSK1437173A 70-79YOA Group vs Zoster-022/006 Pooled Placebo 70-79YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 91.27 · 95% CI 86.04 to 94.85
  • Zoster-022/006 Pooled GSK1437173A >=80YOA Group vs Zoster-022/006 Pooled Placebo >=80YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 91.37 · 95% CI 80.22 to 96.94
  • Zoster-022/006 Pooled GSK1437173A >=70YOA Group vs Zoster-022/006 Pooled Placebo >=70YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 91.30 · 95% CI 86.88 to 94.46
SecondaryNumber of Subjects With Post-herpetic Neuralgia (PHN)

PHN cases in the mTVc.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Post-herpetic Neuralgia (PHN)
ParticipantsZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
Number of Subjects With Post-herpetic Neuralgia (PHN)22422628
Statistical analysis
  • Zoster-022 GSK1437173A 70-79YOA Group vs Zoster-022 Placebo 70-79YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 90.80 · 95% CI 62.57 to 98.95
  • Zoster-022 GSK1437173A >=80YOA Group vs Zoster-022 Placebo >=80YOA Group · Poisson exact test · p = 0.3072 · Vaccine efficacy: 65.76 · 95% CI -91.58 to 96.62
  • Zoster-022 GSK1437173A >=70YOA Group vs Zoster-022 Placebo >=70YOA Group · Poisson exact test · p = <0.0001 · Vaccine efficacy: 85.49 · 95% CI 58.52 to 96.30
SecondaryNumber of Days With Severe 'Worst' HZ-associated Pain

Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Mean · Days
Number of Days With Severe 'Worst' HZ-associated Pain
DaysZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
Number of Days With Severe 'Worst' HZ-associated Pain21.8 ± 31.4198.7 ± 57.7334.6 ± 45.5447.9 ± 100.0850.4 ± 106.5148.5 ± 101.40
Statistical analysis
  • Zoster-022 GSK1437173A 70-79YOA Group vs Zoster-022 Placebo 70-79YOA Group · Poisson exact test · p = 0.3749 · Vaccine efficacy: 21.70 · 95% CI -34.40 to 54.39
  • Zoster-022 GSK1437173A >=80YOA Group vs Zoster-022 Placebo >=80YOA Group · Poisson exact test · p = 0.2466 · Vaccine efficacy: 51.76 · 95% CI -65.55 to 85.95
  • Zoster-022 GSK1437173A >=70YOA Group vs Zoster-022 Placebo >=70YOA Group · Poisson exact test · p = 0.1877 · Vaccine efficacy: 28.40 · 95% CI -17.69 to 56.44
SecondaryNumber of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations

The number of subjects with confirmed HZ related mortality and hospitalizations were tabulated.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations
ParticipantsZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
Mortality000000
Hospitalization000325
Mortality or hospitalization000325
SecondaryNumber of Subjects With Overall Mortality and HZ-related Mortality

The number of subjects with overall mortality and HZ related mortality were tabulated. Evaluation of VE in the reduction of overall and HZ related mortality as per study objective was not performed due to low number of events reported.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Overall Mortality and HZ-related Mortality
ParticipantsZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
Number of Subjects With Overall Mortality and HZ-related Mortality000000
SecondaryNumber of Subjects With Confirmed HZ Episode Related Hospitalizations

Incidence of overall and HZ-related hospitalizations during the study.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Confirmed HZ Episode Related Hospitalizations
ParticipantsZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
Number of Subjects With Confirmed HZ Episode Related Hospitalizations000325
Statistical analysis
  • Zoster-022 GSK1437173A 70-79YOA Group vs Zoster-022 Placebo 70-79YOA Group · Poisson exact test · p = 0.2533 · Vaccine efficacy: 100.00 · 95% CI -144.13 to 100.00
  • Zoster-022 GSK1437173A >=80YOA Group vs Zoster-022 Placebo >=80YOA Group · Poisson exact test · p = 0.5024 · Vaccine efficacy: 100.00 · 95% CI -435.14 to 100.00
  • Zoster-022 GSK1437173A >=70YOA Group vs Zoster-022 Placebo >=70YOA Group · Poisson exact test · p = 0.0636 · Vaccine efficacy: 100.00 · 95% CI -9.92 to 100.00
SecondaryNumber of Subjects With HZ Related Complications

Incidence of HZ complications during the study in subjects with confirmed HZ.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With HZ Related Complications
ParticipantsZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
At least one complication1016410
HZ vasculitis000000
Disseminated Disease000022
Ophthalmic Disease101426
Neurologic Disease000303
Visceral Disease000000
Stroke000000
Statistical analysis
  • Zoster-022 GSK1437173A 70-79YOA Group vs Zoster-022 Placebo 70-79YOA Group · Poisson exact test · p = 0.4947 · Vaccine efficacy: -65.69 · 95% CI -827.06 to 73.62
  • Zoster-022 GSK1437173A >=80YOA Group vs Zoster-022 Placebo >=80YOA Group · Poisson exact test · p = 1.0000 · Vaccine efficacy: 100.00 · 95% CI -558.05 to 100.00
  • Zoster-022 GSK1437173A >=70YOA Group vs Zoster-022 Placebo >=70YOA Group · Poisson exact test · p = 1.0000 · Vaccine efficacy: 0.97 · 95% CI -433.32 to 83.16
SecondaryNumber of Subjects Receiving Pain Medication Associated With HZ

Incidence of use of pain medications throughout the study

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects Receiving Pain Medication Associated With HZ
ParticipantsZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
At least 1 pain medication731012337160
1 pain medication only505431760
2 pain medications only01130434
3 pain medications or more224501666
Statistical analysis
  • Zoster-022 GSK1437173A 70-79YOA Group vs Zoster-022 Placebo 70-79YOA Group · Poisson exact test · p = 0.0112 · Vaccine efficacy: 43.42 · 95% CI 10.77 to 70.53
  • Zoster-022 GSK1437173A >=80YOA Group vs Zoster-022 Placebo >=80YOA Group · Poisson exact test · p = 0.3903 · Vaccine efficacy: 27.03 · 95% CI -26.43 to 73.20
  • Zoster-022 GSK1437173A >=70YOA Group vs Zoster-022 Placebo >=70YOA Group · Poisson exact test · p = 0.0083 · Vaccine efficacy: 39.60 · 95% CI 10.79 to 64.75
SecondaryNumber of Days With Pain Medication Associated With HZ

Incidence of reduction of duration of pain medication associated with HZ throughout the study.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Mean · Days
Number of Days With Pain Medication Associated With HZ
DaysZoster-022 GSK1437173A 70-79YOA GroupZoster-022 GSK1437173A >=80YOA GroupZoster-022 GSK1437173A >=70YOA GroupZoster-022 Placebo 70-79YOA GroupZoster-022 Placebo >=80YOA GroupZoster-022 Placebo >=70YOA Group
Number of Days With Pain Medication Associated With HZ38.7 ± 56.44274.7 ± 337.00109.5 ± 200.88218.6 ± 593.80135.0 ± 207.31199.3 ± 530.60
Statistical analysis
  • Zoster-022 GSK1437173A 70-79YOA Group vs Zoster-022 Placebo 70-79YOA Group · Poisson exact test · p = 0.0232 · Vaccine efficacy: 58.94 · 95% CI 11.45 to 80.96
  • Zoster-022 GSK1437173A >=80YOA Group vs Zoster-022 Placebo >=80YOA Group · Poisson exact test · p = 0.8324 · Vaccine efficacy: -14.56 · 95% CI -303.30 to 67.46
  • Zoster-022 GSK1437173A >=70YOA Group vs Zoster-022 Placebo >=70YOA Group · Poisson exact test · p = 0.0404 · Vaccine efficacy: 49.25 · 95% CI 2.92 to 73.47
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented everyday normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Any Pain, Dose 129726
Grade 3 Pain, Dose 1121
Any Redness, Dose 11433
Grade 3 Redness, Dose 190
Any Swelling, Dose 1852
Grade 3 Swelling, Dose 120
Any Pain, Dose 228223
Grade 3 Pain, Dose 2120
Any Redness, Dose 21373
Grade 3 Redness, Dose 2150
Any Swelling, Dose 2680
Grade 3 Swelling, Dose 270
Any Pain, Across Doses34743
Grade 3 Pain, Across Doses221
Any Redness, Across Doses1985
Grade 3 Redness, Across Doses200
Any Swelling, Across Doses1142
Grade 3 Swelling, Across Doses80
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Any Fatigue, Dose 110456
Grade 3 Fatigue, Dose 184
Related Fatigue, Dose 18534
Any Gastrointestinal, Dose 12528
Grade 3 Gastrointestinal, Dose 132
Related Gastrointestinal, Dose 11614
Any Headache, Dose 17242
Grade 3 Headache, Dose 124
Related Headache, Dose 15827
Any Myalgia, Dose 110627
Grade 3 Myalgia, Dose 162
Related Myalgia, Dose 19116
Any Shivering, Dose 13817
Grade 3 Shivering, Dose 111
Related Shivering, Dose 13212
Any Temperature, Dose 1399
Grade 3 Temperature, Dose 102
Related Temperature, Dose 1314
Any Fatigue, Dose 212239
Grade 3 Fatigue, Dose 290
Related Fatigue, Dose 210530
Any Gastrointestinal, Dose 23719
Grade 3 Gastrointestinal, Dose 231
Related Gastrointestinal, Dose 22613
Any Headache, Dose 27626
Grade 3 Headache, Dose 240
Related Headache, Dose 26320
Any Myalgia, Dose 211318
Grade 3 Myalgia, Dose 270
Related Myalgia, Dose 29416
Any Shivering, Dose 25911
Grade 3 Shivering, Dose 251
Related Shivering, Dose 2479
Any Temperature, Dose 2386
Grade 3 Temperature, Dose 202
Related Temperature, Dose 2352
Any Fatigue, Across Doses16677
Grade 3 Fatigue, Across Doses164
Related Fatigue, Across Doses14052
Any Gastrointestinal, Across Doses5540
Grade 3 Gastrointestinal, Across Doses52
Related Gastrointestinal, Across Doses3821
Any Headache, Across Doses12455
Grade 3 Headache, Across Doses54
Related Headache, Across Doses10437
Any Myalgia, Across Doses15741
Grade 3 Myalgia, Across Doses122
Related Myalgia, Across Doses13729
Any Shivering, Across Doses7522
Grade 3 Shivering, Across Doses62
Related Shivering, Across Doses6416
Any Temperature, Across Doses6213
Grade 3 Temperature, Across Doses02
Related Temperature, Across Doses546
SecondaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within the 30 days (Days 0-29) after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Any unsolicited AE(s)38592263
Grade 3 unsolicited AE(s)485265
Related unsolicited AE(s)2853529
SecondaryNumber of Subjects With Any and Related Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Month 0 to Month 14
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Serious Adverse Events (SAEs)
ParticipantsZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Any SAE(s)891939
Related SAE(s)127
SecondaryNumber of Subjects With Fatal Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Fatal Serious Adverse Events (SAEs)
ParticipantsZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Number of Subjects With Fatal Serious Adverse Events (SAEs)426459
SecondaryNumber of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication

The number of subjects with SAEs related to study participation or concomitant GSK medication were tabulated

Time frame:
During the entire study period (3 to 5 year period following day 0)
Reported as:
Count of participants · Participants
Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication
ParticipantsZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication5784
SecondaryNumber of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
ParticipantsZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Any pIMD9297
Related pIMDs86
SecondaryNumber of Subjects With Any and Related Medically Attended Visits

Occurrence and relationship to vaccination of medically attended visits other than routine health care visits, from Month 0 to Month 8 in all subjects. Medically attended visits were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended visits= Occurrence of any medically attended visits regardless of intensity grade or relation to vaccination.

Time frame:
From Month 0 to Month 8 post-vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Medically Attended Visits
ParticipantsZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Any medically attended visits28822911
Related medically attended visits16566
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA

Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA
ParticipantsZoster-022/006 Pooled GSK1437173A 50-59 YOA GroupZoster-022/006 Pooled GSK1437173A 60-69 YOA GroupZoster-022/006 Pooled GSK1437173A 70-79 YOA GroupZoster-022/006 Pooled GSK1437173A >=80 YOA GroupZoster-022/006 Pooled GSK1437173A >=50 YOA GroupZoster-022/006 Pooled Placebo 50-59 YOA GroupZoster-022/006 Pooled Placebo 60-69 YOA GroupZoster-022/006 Pooled Placebo 70-79 YOA GroupZoster-022/006 Pooled Placebo >=80 YOA GroupZoster-022/006 Pooled Placebo >=50 YOA Group
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA002248229746
Statistical analysis
  • Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group vs Zoster-022/006 Pooled Placebo 50-59 YOA Group · Poisson exact test · p = 0.0081 · Vaccine efficacy: 100.00 · 95% CI 40.88 to 100.00
  • Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group vs Zoster-022/006 Pooled Placebo 60-69 YOA Group · Poisson exact test · p = 0.5097 · Vaccine efficacy: 100.00 · 95% CI -442.83 to 100.00
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ

Occurrence of PHN during the entire study period in all subjects with confirmed HZ.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ
ParticipantsZoster-022/006 Pooled GSK1437173A 50-59 YOA GroupZoster-022/006 Pooled GSK1437173A 60-69 YOA GroupZoster-022/006 Pooled GSK1437173A 70-79 YOA GroupZoster-022/006 Pooled GSK1437173A >=80 YOA GroupZoster-022/006 Pooled GSK1437173A >=50 YOA GroupZoster-022/006 Pooled Placebo 50-59 YOA GroupZoster-022/006 Pooled Placebo 60-69 YOA GroupZoster-022/006 Pooled Placebo 70-79 YOA GroupZoster-022/006 Pooled Placebo >=80 YOA GroupZoster-022/006 Pooled Placebo >=50 YOA Group
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ002248229746
Statistical analysis
  • Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group vs Zoster-022/006 Pooled Placebo 50-59 YOA Group · Poisson exact test · p = 1.0000 · Vaccine efficacy: 100.00 · 95% CI -649.86 to 100.00
  • Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group vs Zoster-022/006 Pooled Placebo 60-69 YOA Group · Poisson exact test · p = 1.0000 · Vaccine efficacy: 100.00 · 95% CI -3938.70 to 100.00
  • Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group vs Zoster-022/006 Pooled Placebo 70-79 YOA Group · Poisson exact test · p = 1.0000 · Vaccine efficacy: 21.60 · 95% CI -149.41 to 78.91
  • Zoster-022/006 Pooled GSK1437173A >=80 YOA Group vs Zoster-022/006 Pooled Placebo >=80 YOA Group · Poisson exact test · p = 0.1528 · Vaccine efficacy: -223.81 · 95% CI -883.05 to 18.84
  • Zoster-022/006 Pooled GSK1437173A >=50 YOA Group vs Zoster-022/006 Pooled Placebo >=50 YOA Group · Poisson exact test · p = 0.5417 · Vaccine efficacy: 0.29 · 95% CI -161.53 to 65.57
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.

The duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.
ParticipantsZoster-022/006 Pooled GSK1437173A 70-79 YOA GroupZoster-022/006 Pooled GSK1437173A >=80 YOA GroupZoster-022/006 Pooled GSK1437173A >=70 YOA GroupZoster-022/006 Pooled Placebo 70-79 YOA GroupZoster-022/006 Pooled Placebo >=80 YOA GroupZoster-022/006 Pooled Placebo >=70 YOA Group
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.1732019361254
Statistical analysis
  • Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group vs Zoster-022/006 Pooled Placebo 70-79 YOA Group · Poisson exact test · p = 0.2885 · Vaccine efficacy: 23.75 · 95% CI -25.80 to 53.78
  • Zoster-022/006 Pooled GSK1437173A >=80 YOA Group vs Zoster-022/006 Pooled Placebo >=80 YOA Group · Poisson exact test · p = 0.1940 · Vaccine efficacy: 54.93 · 95% CI -50.03 to 86.46
  • Zoster-022/006 Pooled GSK1437173A >=70 YOA Group vs Zoster-022/006 Pooled Placebo >=70 YOA Group · Poisson exact test · p = 0.1243 · Vaccine efficacy: 30.48 · 95% CI -10.52 to 56.27
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.

Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Mean · Days
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.
DaysZoster-022/006 Pooled GSK1437173A 70-79 YOA GroupZoster-022/006 Pooled GSK1437173A >=80 YOA GroupZoster-022/006 Pooled GSK1437173A >=70 YOA GroupZoster-022/006 Pooled Placebo 70-79 YOA GroupZoster-022/006 Pooled Placebo >=80 YOA GroupZoster-022/006 Pooled Placebo >=70 YOA Group
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.20.3 ± 29.7198.7 ± 57.7332.1 ± 43.8048.3 ± 96.3445.2 ± 95.5847.5 ± 95.98
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms

Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsZoster-022/006 Pooled GSK1437173A GroupZoster-022/006 Pooled Placebo Group
Any Pain, Dose 11336128
Grade 3 Pain, Dose 1421
Any Redness, Dose 160617
Grade 3 Redness, Dose 1430
Any Swelling, Dose 135517
Grade 3 Swelling, Dose 1170
Any Pain, Dose 21241107
Grade 3 Pain, Dose 2603
Any Redness, Dose 258214
Grade 3 Redness, Dose 2390
Any Swelling, Dose 234410
Grade 3 Swelling, Dose 2150
Any Pain, Across Doses1562199
Grade 3 Pain, Across Doses904
Any Redness, Across Doses85127
Grade 3 Redness, Across Doses700
Any Swelling, Across Doses51925
Grade 3 Swelling, Across Doses300
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = Temperature\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsZoster-022/006 Pooled GSK1437173A GroupZoster-022/006 Pooled Placebo Group
Any Fatigue, Dose 1545231
Grade 3 Fatigue, Dose 13113
Related Fatigue, Dose 1441147
Any Gastrointestinal, Dose 1170123
Grade 3 Gastrointestinal, Dose 1156
Related Gastrointestinal, Dose 110167
Any Headache, Dose 1380189
Grade 3 Headache, Dose 178
Related Headache, Dose 1293132
Any Myalgia, Dose 1530159
Grade 3 Myalgia, Dose 1267
Related Myalgia, Dose 1445101
Any Shivering, Dose 120673
Grade 3 Shivering, Dose 1153
Related Shivering, Dose 117350
Any Temperature, Dose 114234
Grade 3 Temperature, Dose 112
Related Temperature, Dose 111116
Any Fatigue, Dose 2579169
Grade 3 Fatigue, Dose 2534
Related Fatigue, Dose 2495116
Any Gastrointestinal, Dose 218875
Grade 3 Gastrointestinal, Dose 2145
Related Gastrointestinal, Dose 214235
Any Headache, Dose 2455133
Grade 3 Headache, Dose 2302
Related Headache, Dose 238686
Any Myalgia, Dose 2560112
Grade 3 Myalgia, Dose 2424
Related Myalgia, Dose 248475
Any Shivering, Dose 233455
Grade 3 Shivering, Dose 2364
Related Shivering, Dose 229234
Any Temperature, Dose 222430
Grade 3 Temperature, Dose 223
Related Temperature, Dose 218914
Any Fatigue, Across Doses825326
Grade 3 Fatigue, Across Doses7917
Related Fatigue, Across Doses699220
Any Gastrointestinal, Across Doses304172
Grade 3 Gastrointestinal,Across Doses2610
Related Gastrointestinal,Across Doses21091
Any Headache, Across Doses653268
Grade 3 Headache, Across Doses3410
Related Headache, Across Doses547185
Any Myalgia, Across Doses790225
Grade 3 Myalgia, Across Doses6210
Related Myalgia, Across Doses689157
Any Shivering, Across Doses439110
Grade 3 Shivering, Across Doses496
Related Shivering, Across Doses38075
Any Temperature, Across Doses32361
Grade 3 Temperature, Across Doses33
Related Temperature, Across Doses26530
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any,Grade 3 and Related Unsolicited AEs in Subjects ≥ 70 YOA

Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within 30 days (Days 0 - 29) after each vaccination
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any,Grade 3 and Related Unsolicited AEs in Subjects ≥ 70 YOA
ParticipantsZoster-022/006 Pooled GSK1437173A GroupZoster-022/006 Pooled Placebo Group
Any unsolicited AE(s)43662732
Grade 3 unsolicited AE(s)553335
Related unsolicited AE(s)2961578
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related SAEs

Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA. Related SAEs also included any SAEs related to study participation or concurrent GSK medication/vaccine.

Time frame:
From Month 0 to Month 14
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related SAEs
ParticipantsZoster-022/006 Pooled GSK1437173A GroupZoster-022/006 Pooled Placebo Group
Any SAE(s)11171171
Related SAE(s)127
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs

Fatal SAEs during the entire study period in subjects ≥ 70 YOA.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs
ParticipantsZoster-022/006 Pooled GSK1437173A GroupZoster-022/006 Pooled Placebo Group
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs128144
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related pIMDs

Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.

Time frame:
During the entire study period (3 to 5 year period following Day 0)
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related pIMDs
ParticipantsZoster-022/006 Pooled GSK1437173A GroupZoster-022/006 Pooled Placebo Group
Any pIMD(s)110118
Related pIMD(s)88
SecondaryOutcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related Medically Attended Visits

Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.

Time frame:
From Month 0 to Month 8 post-vaccination
Reported as:
Count of participants · Participants
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related Medically Attended Visits
ParticipantsZoster-022/006 Pooled GSK1437173A GroupZoster-022/006 Pooled Placebo Group
Any medically attended visits35933648
Related medically attended visits18080

Adverse events

Collected over Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoster-022 GSK1437173A Group426/6,950 (6.1%)1,153/6,950 (16.6%)3,067/6,950 (44.1%)
Zoster-022 Placebo Group459/6,950 (6.6%)1,214/6,950 (17.5%)610/6,950 (8.8%)
Most frequent serious events
Showing 10 of 955
Most frequent serious events
EventZoster-022 GSK1437173A GroupZoster-022 Placebo Group
PneumoniaInfections and infestations70/695081/6950
Cardiac failureCardiac disorders51/695057/6950
Atrial fibrillationCardiac disorders40/695054/6950
Myocardial infarctionCardiac disorders41/695045/6950
Cerebrovascular accidentNervous system disorders34/695031/6950
Cardiac failure congestiveCardiac disorders23/695033/6950
DeathGeneral disorders17/695029/6950
Acute myocardial infarctionCardiac disorders21/695028/6950
Coronary artery diseaseCardiac disorders28/695025/6950
Urinary tract infectionInfections and infestations28/695024/6950
Most frequent other events
Most frequent other events
EventZoster-022 GSK1437173A GroupZoster-022 Placebo Group
Injection site painGeneral disorders1975/6950148/6950
Injection site erythemaGeneral disorders864/695027/6950
Injection site swellingGeneral disorders613/695016/6950
HeadacheNervous system disorders586/6950243/6950
PyrexiaGeneral disorders535/695052/6950
FatigueGeneral disorders474/6950169/6950
PainGeneral disorders428/695060/6950
MyalgiaMusculoskeletal and connective tissue disorders378/695099/6950
ChillsGeneral disorders353/695039/6950

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zoster-022 GSK1437173A GroupZoster-022 Placebo GroupTotal
Mean75.6 ± 4.775.6 ± 4.775.6 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)Zoster-022 GSK1437173A GroupZoster-022 Placebo GroupTotal
Female378938367625
Male316131146275
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zoster-022 GSK1437173A GroupZoster-022 Placebo GroupTotal
Geographic ancestry — African Heritage / African American7967146
Geographic ancestry — American Indian or Alaskan Native189
Geographic ancestry — Asian - Central/South Asian Heritage369
Geographic ancestry — Asian - East Asian Heritage9079081815
Geographic ancestry — Asian - Japanese Heritage298300598
Geographic ancestry — Asian - South East Asian Heritage8412
Geographic ancestry — Native Hawaiian or Other Pacific Islander336
Geographic ancestry — White - Arabic / North African Heritage404787
Geographic ancestry — White - Caucasian / European Heritage5307530110608
Geographic ancestry — Other304306610
08

Study locations

213 sites
  • GSK Investigational Site
    Mesa, Arizona 85213, United States
  • GSK Investigational Site
    Phoenix, Arizona 85018, United States
  • GSK Investigational Site
    Phoenix, Arizona 85020, United States
  • GSK Investigational Site
    Phoenix, Arizona 85050, United States
  • GSK Investigational Site
    Tucson, Arizona 85704, United States
  • GSK Investigational Site
    Spring Valley, California 91978, United States
  • GSK Investigational Site
    Vista, California 92083, United States
  • GSK Investigational Site
    Clearwater, Florida 33761, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Jacksonville, Florida 32205, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Meridian, Idaho 83642, United States
  • GSK Investigational Site
    Overland Park, Kansas 66212, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Baltimore, Maryland 21209, United States
  • GSK Investigational Site
    Columbia, Maryland 21045, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89104, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89119, United States
  • GSK Investigational Site
    Edison, New Jersey 08817, United States
  • GSK Investigational Site
    Somers Point, New Jersey 08244, United States
  • GSK Investigational Site
    Cary, North Carolina 27518, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Hickory, North Carolina 28602, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28144, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Wadsworth, Ohio 44281, United States
  • GSK Investigational Site
    Carnegie, Pennsylvania 15106, United States
  • GSK Investigational Site
    Pleasant Hills, Pennsylvania 15236, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Greer, South Carolina 29650, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Murray, Utah 84123, United States
  • GSK Investigational Site
    Arlington, Virginia 22203, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Richmond, Virginia 23294, United States
  • GSK Investigational Site
    Winchester, Virginia 22601, United States
  • GSK Investigational Site
    Renton, Washington 98057, United States
  • GSK Investigational Site
    Glebe, New South Wales 2037, Australia
  • GSK Investigational Site
    Maroubra, New South Wales 2035, Australia
  • GSK Investigational Site
    Umina, New South Wales 2257, Australia
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Wollongong, New South Wales 2522, Australia
  • GSK Investigational Site
    Caboolture, Queensland 4510, Australia
  • GSK Investigational Site
    Kippa Ring, Queensland 4021, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Ivanhoe, Victoria 3079, Australia
  • GSK Investigational Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • GSK Investigational Site
    Curitiba/Paraná, Paraná 80810-050, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035003, Brazil
  • GSK Investigational Site
    Curitiba/PR, 80240-280, Brazil
  • GSK Investigational Site
    São Paulo, 04038 002, Brazil
  • GSK Investigational Site
    São Paulo, 04266-010, Brazil
  • GSK Investigational Site
    São Paulo, 04312903, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3P9, Canada
  • GSK Investigational Site
    Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4S 1Y2, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Woodstock, Ontario N4S 5P5, Canada
  • GSK Investigational Site
    Gatineau, Quebec J8Y 6S8, Canada
  • GSK Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1E 7G9, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 2G2, Canada
  • GSK Investigational Site
    Trois Rivières, Quebec G8T 7A1, Canada
  • GSK Investigational Site
    Quebec, G1W 4R4, Canada
  • GSK Investigational Site
    Brno, 662 10, Czechia
  • GSK Investigational Site
    Ceske Budejovice, 370 04, Czechia
  • GSK Investigational Site
    Hradec Kralove, 500 01, Czechia
  • GSK Investigational Site
    Tallinn, 13619, Estonia
  • GSK Investigational Site
    Tartu, 50106, Estonia
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Pori, 28100, Finland
  • GSK Investigational Site
    Seinajoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Cherbourg, 50100, France
  • GSK Investigational Site
    Château Gontier, 53200, France
  • GSK Investigational Site
    Clermont-Ferrand, 63003, France
  • GSK Investigational Site
    Laval, 53000, France
  • GSK Investigational Site
    Laval, 53100, France
  • GSK Investigational Site
    Montrevault, 49110, France
  • GSK Investigational Site
    Muret, 31600, France
  • GSK Investigational Site
    Nantes, 44300, France
  • GSK Investigational Site
    Rosiers d'Egletons, 19300, France
  • GSK Investigational Site
    Saint Cyr Sur Loir, 37540, France

Showing the first 100 of 213 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. PubMed 27626517 ↗
  • Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ; ZOE-50/70 Study Group. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2018 May 5;217(11):1750-1760. doi: 10.1093/infdis/jiy095. PubMed 29529222 ↗
  • Ikematsu H et al. (2018) Efficacy, safety and immunogenicity of new adjuvanted herpes zoster subunit vaccine for Japanese over 50 years old and over 70 years old. Kansenshogaku Zasshi. 92(2):103-114.
  • Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC; ZOE-50/70 Study Group. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17. PubMed 29463421 ↗
  • Kim JH, Diaz-Decaro J, Jiang N, Hwang SJ, Choo EJ, Co M, Hastie A, Hui DSC, Irimajiri J, Lee J, Leung EM, Tang H, Tsuru T, Watson P, Wu Z, Yu CJ, Yuan Y, Zahaf T, Cunningham AL, Schuind A. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults >/= 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum Vaccin Immunother. 2021 Jul 3;17(7):2050-2057. doi: 10.1080/21645515.2020.1859321. Epub 2021 Feb 19. PubMed 33606577 ↗
  • Dagnew AF, Rausch D, Herve C, Zahaf T, Levin MJ, Schuind A; ZOE-50/70 study group. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021 Mar 2;60(3):1226-1233. doi: 10.1093/rheumatology/keaa424. PubMed 32910152 ↗
  • Colindres R, Wascotte V, Brecx A, Clarke C, Herve C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, Cunningham AL. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother. 2020 Nov 1;16(11):2628-2633. doi: 10.1080/21645515.2020.1741312. Epub 2020 Apr 29. PubMed 32347767 ↗
  • Willer DO, Oostvogels L, Cunningham AL, Gervais P, Gorfinkel I, Hyung Kim J, Talarico C, Wascotte V, Zahaf T, Colindres R, Schuind A; ZOE 50/70 study groups. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019 Oct 8;37(43):6262-6267. doi: 10.1016/j.vaccine.2019.09.028. Epub 2019 Sep 16. PubMed 31537443 ↗
  • Lopez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F; ZOE-50/70 Study Group. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine. 2019 Apr 24;37(18):2482-2493. doi: 10.1016/j.vaccine.2019.03.043. Epub 2019 Mar 29. PubMed 30935742 ↗
  • Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, Berglund J, Campora L, de Looze F, Korhonen T, Leung E, Levin M, Volpi A, Johnson RW; ZOE-50/70 Study Group. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. J Gerontol A Biol Sci Med Sci. 2019 Jul 12;74(8):1231-1238. doi: 10.1093/gerona/gly150. PubMed 29955836 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2010 to primary completion in Jul 2015, 59 months.

Results were first posted in Nov 2017, 2 years 3 months after primary completion. A results delay was requested in Aug 2013.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 59 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2010
First posted
Jul 19, 2010
StartActual
Aug 2, 2010
Primary completionActual
Jul 24, 2015
CompletionActual
Jul 24, 2015
Results delay requested
Aug 22, 2013
Results first posted
Nov 20, 2017
Last update
Apr 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01165229
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 19, 2010
Start date
Aug 2, 2010
Primary completion
Jul 24, 2015
Completion
Jul 24, 2015
Results posted
Nov 20, 2017
Last update
Apr 27, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion